文献速递脑血管病

基线血压对MR CLEAN研究中动脉内治疗获益与安全性的影响

Baseline Blood Pressure Effect on the Benefit and Safety of Intra-Arterial Treatment in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands).
PubMed 文献 · Stroke · 2017-04-21

该研究为MR CLEAN试验的事后分析,评估基线血压与90天功能结局、症状性颅内出血及动脉内治疗(IAT)效果的关系。结果显示基线收缩压与功能结局呈U型相关,较高收缩压与症状性颅内出血相关,但血压与IAT的获益或安全性无交互作用,绝对获益在整个收缩压范围内均存在。

要点

  • 基线收缩压与90天功能结局呈U型相关,过低或过高均与不良结局相关。
  • 收缩压每升高10 mm Hg,症状性颅内出血的调整比值比为1.25(95%CI 1.09-1.44)。
  • 血压与IAT的获益或安全性无交互作用,整个收缩压范围内IAT绝对获益均明显。

核心结论

  • 血压不影响由近端颅内血管闭塞所致急性缺血性卒中患者接受IAT的获益或安全性。
  • 数据不提供基于血压而暂缓或延迟IAT的依据。

研究设计与样本

  • MR CLEAN试验的事后分析,基线血压在IAT或卒中单元入院前测量。
  • 采用序数逻辑回归和逻辑回归分析基线血压与90天改良Rankin量表评分及安全性参数的关联。
  • 通过乘法交互项检验血压对IAT效果的影响。

主要发现

  • 收缩压与功能结局相关性最佳,呈U型;低和高的基线收缩压均与不良功能结局相关。
  • 较高的收缩压与症状性颅内出血相关(调整比值比,收缩压每升高10 mm Hg为1.25 [95%CI 1.09-1.44])。
  • 收缩压与IAT之间在功能结局、症状性颅内出血或其他安全性参数上无交互作用;IAT的绝对获益在整个收缩压范围内明显。
  • 舒张压也得到相同发现。

临床怎么用

  • 对于近端颅内血管闭塞的急性缺血性卒中患者,不应仅基于基线血压水平而决定暂缓或延迟IAT。
  • 基线收缩压较高时需警惕症状性颅内出血风险增加。

局限性

  • 本研究为MR CLEAN试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: High blood pressure (BP) is associated with poor outcome and the occurrence of symptomatic intracranial hemorrhage in acute ischemic stroke. Whether BP influences the benefit or safety of intra-arterial treatment (IAT) is not known. We aimed to assess the relation of BP with functional outcome, occurrence of symptomatic intracranial hemorrhage and effect of IAT. METHODS: This is a post hoc analysis of the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands). BP was measured at baseline, before IAT or stroke unit admission. We estimated the association of baseline BP with the score on the modified Rankin Scale at 90 days and safety parameters with ordinal and logistic regression analysis. Effect of BP on the effect of IAT was tested with multiplicative interaction terms. RESULTS: Systolic BP (SBP) had the best correlation with functional outcome. This correlation was U-shaped; both low and high baseline SBP were associated with poor functional outcome. Higher SBP was associated with symptomatic intracranial hemorrhage (adjusted odds ratio, 1.25 for every 10 mm Hg higher SBP [95% confidence interval, 1.09-1.44]). Between SBP and IAT, there was no interaction for functional outcome, symptomatic intracranial hemorrhage, or other safety parameters; the absolute benefit of IAT was evident for the whole SBP range. The same was found for diastolic BP. CONCLUSIONS: BP does not affect the benefit or safety of IAT in patients with acute ischemic stroke caused by proximal intracranial vessel occlusion. Our data provide no arguments to withhold or delay IAT based on BP. CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique identifier: ISRCTN10888758.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mulder MJHL, Ergezen S, Lingsma HF, et al. Baseline Blood Pressure Effect on the Benefit and Safety of Intra-Arterial Treatment in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands). Stroke. 2017. PMID: 28432266. doi:10.1161/STROKEAHA.116.016225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。